top of page
The Professional Network for Healthcare Experts
Escugen and Sovran expand collaboration to co-develop pan-tumour bispecific ADC
Escugen Biotechnology and Sovran Biosciences have expanded their oncology collaboration with a co-development agreement for a pan-tumour bispecific antibody-drug conjugate.
nuaxia
Sep 172 min read
Medicus Pharma licenses Pfizer CD228V antibody-drug conjugate in deal worth more than $1bn
Medicus Pharma has secured exclusive worldwide rights to Pfizer's CD228-targeted antibody-drug conjugate PF-08046031 in an oncology licensing agreement potentially worth more than $1 billion.
nuaxia
Sep 142 min read
Cipla licenses HER2 bispecific ADC TQB2102 from Sino Biopharmaceutical
The agreement gives Cipla exclusive rights to develop and commercialise the investigational HER2-targeted bispecific antibody-drug conjugate TQB2102 across India, South Africa and five additional emerging markets.
nuaxia
Sep 22 min read
bottom of page